Ionis Pharmaceuticals, Inc.

Today is #NationalTriglyceridesDay! We’re raising awareness about the importance of maintaining optimal triglyceride levels and the health risks associated with high triglycerides.      During your next physical exam, ask your doctor about your triglycerides and how to maintain optimal levels.     Learn more about triglycerides and their impact on overall health: https://lnkd.in/edid4bR8

Tracy Palmer Berns, J.D., SVP and Chief Compliance & Quality Assurance Officer at Ionis and Executive Sponsor of EmpowHER, our women’s employee resource group, reflects on what #WomensHistoryMonth means to her and how that influences her as a leader at our company. Learn more about EmpowHER and our culture of belonging at Ionis: https://lnkd.in/e_UggfRn

Maintaining a low-fat diet is an important component of managing diseases related to severely elevated triglycerides. And for individuals #livingwithFCS (familial chylomicronemia syndrome), a rare, genetic and burdensome form of severe hypertriglyceridemia (sHTG), daily fat intake should be no more than 20 grams.     Consuming even a small amount of fat can cause painful physical symptoms. For those who participated in the poll to test your knowledge of what foods are equivalent to 20 grams of fat, the correct answer is 1 tablespoon of olive oil.    Learn more about what an FCS-friendly diet looks like: https://lnkd.in/edid4bR8

Today we announced an expanded partnership with Sobi, granting them exclusive commercialization rights in countries outside the U.S., Canada and China for olezarsen.       Read more about today’s news: https://lnkd.in/eJr_56bZ   #raredisease 

People #livingwithFCS must adhere to a low-fat diet of <20g daily. Let’s test your knowledge.

Today, our CEO Brett P. Monia, PhD had the incredible honor of ringing the Nasdaq Opening Bell to celebrate our recent FDA approval for the treatment of FCS - our first independent medicine! For more than three decades, we’ve been at the forefront of RNA-targeted medicine, pioneering breakthroughs that were once thought impossible. And now we’re poised for even greater impact as a fully integrated commercial-stage biotechnology company! Today’s celebration wouldn’t have been possible without the dedication of our employees, the trust of our partners, and—most importantly—the resilience of the patients we serve. To the Ionis team, our investors and our supporters: thank you for believing in the power of what we do.

In the past week, we had the pleasure of partnering with two exceptional organizations to share our passion for science and biotechnology and help educate and prepare a new generation for careers in related fields. First, we joined industry peers to facilitate interactive activities for underserved students at MANA de San Diego STEAM Pi day celebration. On Tuesday, we hosted the Young Women In Bio career panel at our Carlsbad campus—a platform for accomplished professionals to share their career journeys, insights, and advice, inspiring and guiding young women. It was a privilege to partner with Scientella and Aroga Biosciences to share our passion and knowledge with such energetic and engaged future scientists. 

DYK: people living with transthyretin amyloidosis (#ATTR) can experience multiple symptoms that may seem unrelated? In March, we join the community in recognizing #AmyloidosisAwarenessMonth. ATTR amyloidosis symptoms may vary from person to person and progress over time, so education about this #raredisease may lead to quicker diagnosis, identification of a treatment plan and a better journey for patients. Learn more about ATTR amyloidosis: https://lnkd.in/etb8dfX4

HCPs: Unsure how to distinguish familial chylomicronemia syndrome (FCS) from other causes of elevated triglycerides? A clinical diagnostic scoring tool is now available that can help with diagnosis of this #raredisease on the basis of common clinical and laboratory tests. To learn more and access the North American FCS Scoring Calculator: https://lnkd.in/ecHN_XyD

We were honored to join top academics, biotech innovators, and up-and-coming organizations at RNA at the Bench and Bedside IV at the end of last year. This event continues to be a catalyst for collaboration, knowledge-sharing, and inspiration. At Ionis, we're proud to be part of this dynamic community and see real momentum year over year as these conversations and partnerships continue to shape future innovations in science and medicine. https://lnkd.in/e4NRU2Cn